These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25868013)

  • 1. Expanding the evidence base supporting shorter treatment durations for multidrug-resistant tuberculosis.
    Nuermberger E; Yew WW
    Int J Tuberc Lung Dis; 2015 May; 19(5):497-8. PubMed ID: 25868013
    [No Abstract]   [Full Text] [Related]  

  • 2. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistant TB: fully oral regimens should help improve compliance, says WHO.
    Murphy D
    BMJ; 2018 Aug; 362():k3610. PubMed ID: 30131439
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
    Jiang RH; Xu HB; Li L
    Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis.
    Pasipanodya J; Srivastava S; Gumbo T
    J Infect Dis; 2015 Jul; 212(1):166-7. PubMed ID: 25649174
    [No Abstract]   [Full Text] [Related]  

  • 6. MDR tuberculosis and non-compliance with therapy.
    Cox H; Hughes J; Ford N; London L
    Lancet Infect Dis; 2012 Mar; 12(3):178; author reply 178-9. PubMed ID: 22361422
    [No Abstract]   [Full Text] [Related]  

  • 7. Adherence and acquired drug-resistance in tuberculosis: wisdom stood on its head.
    Kadhiravan T
    Indian J Chest Dis Allied Sci; 2013; 55(1):9-10. PubMed ID: 23798083
    [No Abstract]   [Full Text] [Related]  

  • 8. MDR tuberculosis and non-compliance with therapy.
    Ereqat S; Spigelman M; Bar-Gal GK; Ramlawi A; Abdeen Z
    Lancet Infect Dis; 2011 Sep; 11(9):662. PubMed ID: 21867955
    [No Abstract]   [Full Text] [Related]  

  • 9. Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?
    Bastard M; Bonnet M; du Cros P; Khamraev AK; Hayrapetyan A; Kimenye K; Khurkhumal S; Dlamini T; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Am J Respir Crit Care Med; 2015 Feb; 191(3):355-8. PubMed ID: 25635495
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multi-drug resistance of tuberculosis: 81 patients monitored in an Ivory Coast pneumology unit].
    Horo K; Aka-Danguy E; Kouassi Boko A; N'gom AS; Gode CV; Ahui Brou JM; Motuom AF; Yacouba T; Koante-Kone F; Tcharman MT; Koffi N
    Rev Pneumol Clin; 2011 Apr; 67(2):82-8. PubMed ID: 21497721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and therapeutic effect of drug-resistant tuberculosis in children].
    Liao Q; Tan S; Zhu Y; Wan CM; Deng SY; Shu M
    Zhonghua Er Ke Za Zhi; 2017 Feb; 55(2):100-103. PubMed ID: 28173646
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
    Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Guglielmetti L; Jaspard M; Le Dû D; Lachâtre M; Marigot-Outtandy D; Bernard C; Veziris N; Robert J; Yazdanpanah Y; Caumes E; Fréchet-Jachym M;
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of multidrug-resistant tuberculosis treatment in Ivory Coast from 2008 to 2010].
    Ahui BJ; Horo K; Bakayoko AS; Kouassi AB; Anon JC; Brou-Gode VC; Koffi MO; Itchy MV; N'Gom AS; N'Goran NB; Aka-Danguy E
    Rev Pneumol Clin; 2013 Dec; 69(6):315-9. PubMed ID: 24183291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant tuberculosis: treatment is empirical, for want of robust trials.
    Prescrire Int; 2014 Oct; 23(153):245-6. PubMed ID: 25964976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis.
    Soumakis SA; Berg D; Harris HW
    Clin Infect Dis; 1998 Oct; 27(4):910-1. PubMed ID: 9798062
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of multidrug-resistant tuberculosis: definition of the outcome 'failure'.
    Chiang CY; Van Deun A; Trébucq A; Heldal E; Caminero JA; Aït-Khaled N
    Int J Tuberc Lung Dis; 2011 Jan; 15(1):4-5. PubMed ID: 21276289
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug susceptibility of tuberculosis isolates in Kansas, 1992-1993.
    Kans Med; 1994 Jun; 95(6):147-8. PubMed ID: 7933767
    [No Abstract]   [Full Text] [Related]  

  • 20. Bedaquiline in multidrug-resistant pulmonary tuberculosis GENESIS-SEFH drug evaluation report.
    Borrego Izquierdo Y; López Briz E; Márquez Saavedra E
    Farm Hosp; 2015 Jan; 39(1):1-5. PubMed ID: 25680429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.